FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899684895> ?p ?o ?g. }

• W2899684895 endingPage "108" @default.
• W2899684895 startingPage "100" @default.
• W2899684895 abstract "Denosumab is gradually applied to refractory or unresectable giant cell tumour of the bone. Whether denosumab can effectively reduce the blood supply of tumour and bring benefit is worthy of study. The aim of the study is to evaluate the related changes after treatment: blood supply, surgical plan downstaging, surgical difficulty and oncological prognosis.A self-case-control study was performed from June 2014 to November 2016, and 18 patients were enrolled. Patients received subcutaneous denosumab 120 mg every 4 weeks preoperatively, with additional doses administered on Days 8 and 15 during the first month of therapy. The initial treatment duration was 12 weeks. After 12 weeks treatment, enhanced CT examination was performed for evaluating whether surgical treatment was practicable. The patients received preoperative denosumab treatment for 5 (median 3, range 3-12) months in average. The microvessel density of tumour samples was calculated for evaluating tumour blood supply. The computed tomography (CT) enhancement rate was compared before and after treatment. The related changes of parameters were recorded as the following: clinical benefits, serious side effects, enhancement rate of CT, surgical plans, intraoperative blood loss, operative time, surgical difficulty, histological changes and local recurrence. The patients were followed up every 3 months postoperatively.The average CT enhancement rate of lesions was 2.08 and 1.40 before and after treatment (p = 0.000), respectively. The unenhanced CT value was significantly increased after treatment (p = 0.038). The CT enhancement rate changed more significantly in pelvic or sacral lesions than that in limb lesions (p = 0.024). Sixteen cases underwent final surgery, and surgical plan was downstaged. The histological examination showed tumour cells were significantly reduced or even disappeared after treatment. The microvessel density decreased significantly after treatment. The mean postoperative follow-up was 18.8 (10-31) months, and five patients had local recurrence. The high local recurrence rate (4/6) in sacral tumours may be related to the increased difficulty of curettage.Denosumab treatment can reduce the blood supply of giant cell tumour. The sacral or pelvic lesions changed more significantly than limb lesions. The surgical plan downstaging can also be achieved. The clear margin after denosumab treatment facilitated tumour resection but, increased difficult in curettage surgery, and high recurrence rate of sacral tumour is being concerned.Denosumab is a new type of humanized monoclonal antibody which showed some effect in the treatment giant cell tumor of bone. Pre-operative treatment with denosamub can reduce intra-operative blood loss and down-stage surgical plan in suitable cases." @default.
• W2899684895 created "2018-11-16" @default.
• W2899684895 creator A5027377891 @default.
• W2899684895 creator A5055985568 @default.
• W2899684895 creator A5059407571 @default.
• W2899684895 creator A5078949281 @default.
• W2899684895 creator A5080914162 @default.
• W2899684895 creator A5088151792 @default.
• W2899684895 date "2019-07-01" @default.
• W2899684895 modified "2023-10-01" @default.
• W2899684895 title "Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed?" @default.
• W2899684895 cites W1507649428 @default.
• W2899684895 cites W1572906866 @default.
• W2899684895 cites W1886239876 @default.
• W2899684895 cites W1967530422 @default.
• W2899684895 cites W1997410071 @default.
• W2899684895 cites W2011190829 @default.
• W2899684895 cites W2020210238 @default.
• W2899684895 cites W2028541032 @default.
• W2899684895 cites W2034007734 @default.
• W2899684895 cites W2034391570 @default.
• W2899684895 cites W2034585055 @default.
• W2899684895 cites W2048299560 @default.
• W2899684895 cites W2063676540 @default.
• W2899684895 cites W2066374389 @default.
• W2899684895 cites W2076395246 @default.
• W2899684895 cites W2084567408 @default.
• W2899684895 cites W2088506163 @default.
• W2899684895 cites W2101687609 @default.
• W2899684895 cites W2123384771 @default.
• W2899684895 cites W2143218825 @default.
• W2899684895 cites W2159152276 @default.
• W2899684895 cites W2170218902 @default.
• W2899684895 cites W2212487443 @default.
• W2899684895 cites W2263202834 @default.
• W2899684895 cites W2318038655 @default.
• W2899684895 cites W2496318089 @default.
• W2899684895 doi "https://doi.org/10.1016/j.jot.2018.10.003" @default.
• W2899684895 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6718948" @default.
• W2899684895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31508313" @default.
• W2899684895 hasPublicationYear "2019" @default.
• W2899684895 type Work @default.
• W2899684895 sameAs 2899684895 @default.
• W2899684895 citedByCount "13" @default.
• W2899684895 countsByYear W28996848952020 @default.
• W2899684895 countsByYear W28996848952021 @default.
• W2899684895 countsByYear W28996848952022 @default.
• W2899684895 countsByYear W28996848952023 @default.
• W2899684895 crossrefType "journal-article" @default.
• W2899684895 hasAuthorship W2899684895A5027377891 @default.
• W2899684895 hasAuthorship W2899684895A5055985568 @default.
• W2899684895 hasAuthorship W2899684895A5059407571 @default.
• W2899684895 hasAuthorship W2899684895A5078949281 @default.
• W2899684895 hasAuthorship W2899684895A5080914162 @default.
• W2899684895 hasAuthorship W2899684895A5088151792 @default.
• W2899684895 hasBestOaLocation W28996848951 @default.
• W2899684895 hasConcept C121332964 @default.
• W2899684895 hasConcept C126322002 @default.
• W2899684895 hasConcept C126838900 @default.
• W2899684895 hasConcept C141071460 @default.
• W2899684895 hasConcept C142424586 @default.
• W2899684895 hasConcept C2776286101 @default.
• W2899684895 hasConcept C2776541429 @default.
• W2899684895 hasConcept C2993270971 @default.
• W2899684895 hasConcept C71924100 @default.
• W2899684895 hasConcept C87355193 @default.
• W2899684895 hasConceptScore W2899684895C121332964 @default.
• W2899684895 hasConceptScore W2899684895C126322002 @default.
• W2899684895 hasConceptScore W2899684895C126838900 @default.
• W2899684895 hasConceptScore W2899684895C141071460 @default.
• W2899684895 hasConceptScore W2899684895C142424586 @default.
• W2899684895 hasConceptScore W2899684895C2776286101 @default.
• W2899684895 hasConceptScore W2899684895C2776541429 @default.
• W2899684895 hasConceptScore W2899684895C2993270971 @default.
• W2899684895 hasConceptScore W2899684895C71924100 @default.
• W2899684895 hasConceptScore W2899684895C87355193 @default.
• W2899684895 hasLocation W28996848951 @default.
• W2899684895 hasLocation W28996848952 @default.
• W2899684895 hasLocation W28996848953 @default.
• W2899684895 hasLocation W28996848954 @default.
• W2899684895 hasOpenAccess W2899684895 @default.
• W2899684895 hasPrimaryLocation W28996848951 @default.
• W2899684895 hasRelatedWork W2003938723 @default.
• W2899684895 hasRelatedWork W2047967234 @default.
• W2899684895 hasRelatedWork W2118496982 @default.
• W2899684895 hasRelatedWork W2351796763 @default.
• W2899684895 hasRelatedWork W2439875401 @default.
• W2899684895 hasRelatedWork W2567738959 @default.
• W2899684895 hasRelatedWork W2906311539 @default.
• W2899684895 hasRelatedWork W4238867864 @default.
• W2899684895 hasRelatedWork W4247326581 @default.
• W2899684895 hasRelatedWork W2525756941 @default.
• W2899684895 hasVolume "18" @default.
• W2899684895 isParatext "false" @default.
• W2899684895 isRetracted "false" @default.
• W2899684895 magId "2899684895" @default.
• W2899684895 workType "article" @default.